Clinical significance of BRAF mutations in metastatic melanoma

被引：51

作者：

Chang D.Z. ^{[1
]}

Panageas K.S. ^{[2
]}

Osman I. ^{[3
]}

Polsky D. ^{[3
]}

Busam K. ^{[4
]}

Chapman P.B. ^{[1
]}

机构：

[1] Department of Medicine, Memorial Sloan-Kettering Cancer Ctr., New York, NY

[2] Dept. of Epidemiology/Biostatistics, Memorial Sloan-Kettering Cancer Ctr., New York, NY

[3] R. O. Perelman Dept. of Dermatology, New York University School of Med., New York, NY

[4] Department of Pathology, Memorial Sloan-Kettering Cancer Ctr., New York, NY

来源：

Journal of Translational Medicine | / 2卷 / 1期

关键词：

BRAF mutation; Clinical significance; Metastatic melanoma;

D O I：

10.1186/1479-5876-2-46

中图分类号：

学科分类号：

摘要：

Forty to eighty percent of melanoma tumors have activating mutations in BRAF although the clinical importance of these mutations is not clear. We previously reported an analysis of BRAF mutations in metastatic melanoma samples from 68 patients. In this study, we correlated patient baseline characteristics, prognostic factors, and/or clinical outcomes with the presence of BRAF mutations. No significant differences were observed in age, gender, location of primary melanoma, stage at the diagnosis, and depth of primary tumor between patients with and without BRAF mutations. Melanomas harboring BRAF mutations were more likely to metastasize to liver (P = 0.02) and to metastasize to multiple organs (P = 0.048). Neither time to progression to stage IV nor overall survival were associated with BRAF mutations. In conclusion, we observed no significant differences in clinical characteristics or outcomes between melanomas with or without BRAF mutations. Although there was an increased frequency of liver metastasis and tendency to metastasize to multiple organs in tumors with BRAF mutations, there was no detectable effect on survival. Future prospective studies should include analysis of whether BRAF mutations in melanoma tumors correlate with an increased tendency to metastasize to liver or to multiple organs. © 2004 Chang et al; licensee BioMed Central Ltd.

引用

页数：5

共 15 条

[1]

Govindarajan B., Bai X., Cohen C., Zhong H., Kilroy S., Louis G., Moses M., Arbiser J.L., Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling, J. Biol. Chem., 278, pp. 9790-9795, (2003)

[2]

Cohen C., Zavala-Pompa A., Sequeira J.H., Shoji M., Sexton D.G., Cotsonis G., Cerimele F., Govindarajan B., Macaron N., Arbiser J.L., Mitogen-actived protein kinase activation is an early event in melanoma progression, Clin. Cancer Res., 8, pp. 3728-3733, (2002)

[3]

Satyamoorthy K., Li G., Gerrero M.R., Brose M.S., Volpe P., Weber B.L., Van Belle P., Elder D.E., Herlyn M., Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation, Cancer Res., 63, pp. 756-759, (2003)

[4]

Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung

[5]

Brose M.S., Volpe P., Feldman M., Kumar M., Rishi I., Gerrero R., Einhorn E., Herlyn M., Minna J., Nicholson A., Roth J.A., Albelda S.M., Davies H., Cox C., Brignell G., Stephens P., Futreal P.A., Wooster R., Stratton M.R., Weber B.L., BRAF and RAS Mutations in Human Lung Cancer and Melanoma, Cancer Res., 62, pp. 6997-7000, (2002)

[6]

Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M., Tuveson D.A., Suppression of BRAF(V599E) in human melanoma abrogates transformation, Cancer Res., 63, pp. 5198-5202, (2003)

[7]

Gorden A., Osman I., Gai W., He D., Huang W., Davidson A., Houghton A.N., Busam K., Polsky D., Analysis of BRAF and N-RAS Mutations in Metastatic Melanoma Tissues, Cancer Res., 63, pp. 3955-3957, (2003)

[8]

Edwards R.H., Ward M.R., Wu H., Medina C.A., Brose M.S., Volpe P., Nussen-Lee S., Haupt H.M., Martin A.M., Herlyn M., Lessin S.R., Weber B.L., Absence of BRAF mutations in UV-protected mucosal melanomas, J. Med. Genet., 41, pp. 270-272, (2004)

[9]

Cohen Y., Rosenbaum E., Begum S., Goldenberg D., Esche C., Lavie O., Sidransky D., Westra W.H., Exon 15 BRAF Mutations Are Uncommon in Melanomas Arising in Nonsun-Exposed Sites, Clin. Cancer Res., 10, pp. 3444-3447, (2004)

[10]

Pollock P.M., Harper U.L., Hansen K.S., Yudt L.M., Stark M., Robbins C.M., Moses T.Y., Hostetter G., Wagner U., Kakareka J., Salem G., Pohida T., Heenan P., Duray P., Kallioniemi O., Hayward N.K., Trent J.M., Meltzer P.S., High frequency of BRAF mutations in nevi, Nat. Genet., 33, pp. 19-20, (2003)

← 1 2 →